Search results for "IMMUNOLOGY"

showing 10 items of 9651 documents

Modulation of type II collagen-induced arthritis in DBA/1 mice by intravenous application of a peptide from the C1q-A chain.

1992

In this report we are able to show that intravenous (i.v.) application (day 0) of a nonapeptide (residues 26-34) from the human C1q A-chain (designated peptide A-C1q) prior to intradermal (i.d.) administration of chicken type II collagen (CII) in arthritis-susceptible DBA/1 mice (H2q), leads to abrogation of polymorphonuclear neutrophil (PMN) invasion into the joints. This nonapeptide exhibits epitope characteristics and high homology to residues 137-147 of CB11 (a cyanogen bromide fragment of chicken CII, known to contain both arthritis inducing and suppressing determinants). Arthritis index was lowest in animals pretreated i.v. with CII (as internal control), though animals pretreated i.v…

musculoskeletal diseasesMaleInjections IntradermalImmunologyMolecular Sequence DataType II collagenArthritischemical and pharmacologic phenomenaPeptideEpitopechemistry.chemical_compoundMiceAntigenAdjuvants ImmunologicmedicineImmunology and AllergyAnimalsAmino Acid Sequenceskin and connective tissue diseasesPeptide sequencechemistry.chemical_classificationbiologyArthritisComplement C1qHematologymedicine.diseaseMolecular biologyPeptide FragmentschemistryMice Inbred DBAImmunologyAntibody FormationInjections Intravenousbiology.proteinCyanogen bromideCollagenAntibodyOligopeptidesImmunobiology
researchProduct

AB0465 Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity

2013

Background Rheumatoid arthritis (RA) is conventionally defined as moderate when the disease activity score assessed in 28 joints (DAS28) is ≥3.2, and high disease with DAS28 >5.1 Objectives Aim of this analysis was to evaluate the rate of remission and LDA (low disease activity), in RA patients starting etanercept therapy with moderate disease activity in the real world settings Methods The clinical records were retrospectively analysed from the Italian nationwide registry, called GISEA (Gruppo Italiano Studio Early Arthritis). RA patients with moderate (Mod-RA) and high (H-RA) disease activity (DAS28 >3.2) with incomplete response to conventional DMARDs and beginning a treatment with etane…

musculoskeletal diseasesModerate to severemedicine.medical_specialtybusiness.industryImmunologySevere diseaseDiseasemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyEtanerceptSurgeryRheumatologyStandard careRheumatoid arthritisInternal medicineImmunology and AllergyMedicineEtanercept therapybusinessEarly arthritismedicine.drugAnnals of the Rheumatic Diseases
researchProduct

The Pro-Inflammatory IL23/IL23R/IL17 Axis Is Active in IL23R-Expressing Circulating CLL Cells in Patients with Poor Prognosis

2012

Abstract Abstract 3889 Inflammatory cytokines play a biological role in the pathogenesis of Chronic lymphocytic leukemia (CLL). IL23 is a pro-inflammatory cytokine involved in T-cell responses and in tissue remodeling. It has been shown that the IL23 receptor (IL23R) is up-regulated in primary acute lymphoblastic leukemia (ALL) cells, and that IL23 inhibits ALL cell growth. Nevertheless, the anti-tumor function of IL23 still remains controversial. The role of the IL23R/IL23 axis in CLL has not been investigated so far. Herein we evaluated the expression pattern of IL23R/IL23 axis and its correlation with progression free survival (PFS) in CLL patients. A total of 233 newly diagnosed Binet s…

musculoskeletal diseasesPathologymedicine.medical_specialtyChronic lymphocytic leukemiaImmunologyContext (language use)Cell BiologyHematologyCD38Biologymedicine.diseaseBiochemistrymedicine.anatomical_structureAcute lymphocytic leukemiamedicineImmunohistochemistryBone marrowProgression-free survivalLymph nodeBlood
researchProduct

Lymphatic vessels of the dura mater: a new discovery?

2015

Aspelund et al. discover the presence of a lymphatic vessel network in the dura mater of the mouse brain and show that these dural lymphatic vessels are important for the clearance of macromolecules from the brain.

musculoskeletal diseasesPathologymedicine.medical_specialtyHistologyMacromolecular SubstancesDura materCentral nervous systemNeuroimmunologyBlood–brain barrierBlood-brain barrier; Brain; Central nervous system; Dura mater; Lymphatics; Mascagni; Neuroanatomy; Neuroimmunology; Transudate; Anatomy; Histology; Developmental Biology; Ecology Evolution Behavior and Systematics; Molecular Biology; Cell BiologyTransudateLymphatic SystemMatters ArisingmedicineAnimalsDura materMolecular BiologyEcology Evolution Behavior and SystematicsBlood-brain barrierCerebrospinal Fluidintegumentary systembusiness.industrySettore BIO/16 - Anatomia UmanaBrief Definitive ReportMascagniBrainExtracellular FluidAnatomyCell Biologymusculoskeletal systemEcology Evolution Behavior and SystematicTransudatenervous system diseasesNeuroanatomyNeuroimmunologymedicine.anatomical_structureLymphatic systemnervous systemCentral nervous systemLymph NodesAnatomybusinessLymphaticNeuroanatomyDevelopmental BiologyJournal of anatomy
researchProduct

Bindungsstudien mit Ulex Europaeus Agglutinin I (UEA-I) am Gefäßendothel der Synovialmembran*

2008

The lectin binding sites of the synovium of patients with rheumatoid arthritis and osteoarthritis were investigated. It was shown that Ulex europaeus agglutinin is a constant marker of the vascular endothelium and is not induced during the course of inflammatory process in rheumatoid arthritis.

musculoskeletal diseasesPathologymedicine.medical_specialtybiologyEndotheliumChemistryArthritisOsteoarthritismedicine.diseasebiology.organism_classificationUlex europaeusVascular endotheliumAgglutininmedicine.anatomical_structureRheumatoid arthritisLectin bindingImmunologymedicineOrthopedics and Sports MedicineSurgeryskin and connective tissue diseasesZeitschrift für Orthopädie und ihre Grenzgebiete
researchProduct

A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis

2014

In contrast with the numerous controlled trials conducted in polyarticular or systemic juvenile idiopathic arthritis (JIA), little evidence-based information is available for oligoarticular JIA. As a result, the management of children with this subtype, which is the most prevalent in Western countries, is largely empiric. Intra-articular corticosteroid (IAC) injection is the therapy of first choice for oligoarthritis in many pediatric rheumatology centers. However, although IAC injections are usually highly efficacious, relapses of synovitis are common and sometimes occur only a few months after the procedure. It is still unclear whether concomitant administration of methotrexate (MTX) may …

musculoskeletal diseasesPediatricsmedicine.medical_specialtyArthritislaw.inventionSettore MED/38 - Pediatria Generale E SpecialisticaRheumatologyRandomized controlled triallawInternal medicineSynovitismedicineImmunology and AllergyPediatrics Perinatology and Child Healthskin and connective tissue diseasesmethotrexate oligoarticular juvenile idiopathic arthritisOligoarthritisbusiness.industrymedicine.diseaseRheumatologyConcomitantPoster PresentationPediatrics Perinatology and Child HealthMethotrexateOligoarticular Juvenile Idiopathic Arthritisbusinessmedicine.drugPediatric Rheumatology
researchProduct

Identification of the Yersinia enterocolitica urease beta subunit as a target antigen for human synovial T lymphocytes in reactive arthritis.

1993

The local T-cell response to bacterial antigens is involved in the pathogenesis of reactive arthritis (ReA). Here, we have identified a 19-kDa antigen of Yersinia enterocolitica O:9 recognized by Yersinia-specific synovial fluid CD4+ T cells in two patients with Yersinia-induced ReA. N-terminal amino acid sequencing of this protein revealed that it was identical to the 19-kDa urease beta subunit of Y. enterocolitica O:9. This protein has previously been shown to be arthritogenic in preimmunized rats after intra-articular injection. Analysis of the T-cell response to this protein showed that it contains several T-cell epitopes, one of which cross-reacts with other enterobacteria not able to …

musculoskeletal diseasesProtein subunitT-LymphocytesImmunologyMolecular Sequence DataBiologyLymphocyte ActivationMicrobiologyEpitopeMicrobiologyAntigenProhibitinsSynovial FluidSynovial fluidHumansAmino Acid SequenceYersinia enterocoliticaHLA-DR AntigenYersinia enterocoliticaAntigens BacterialSequence Homology Amino AcidArthritisT lymphocyteHLA-DR Antigensbiology.organism_classificationbacterial infections and mycosesUreaseInfectious DiseasesParasitologyBacterial antigenResearch Article
researchProduct

Trastuzumab-emtansine induced pleural and pericardial effusions

2021

Introduction Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1). Case report We report the first case of T-DM1-associated pleural and pericardial effusions three weeks after the second course of T-DM1 in a patient with breast cancer. Drug-induced pleural and pericardial effusions was implicated in the absence of other etiologies. The Naranjo Scale indicated a probable drug-induced adverse reaction. Management & outcome: The patient fully recovered after thoracentesis and discontinuation of T-DM1. The patient h…

musculoskeletal diseasesReceptor ErbB-2medicine.drug_classBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal HumanizedMonoclonal antibodyPericardial effusionPericardial Effusion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTrastuzumabmedicineHumansMaytansinePharmacology (medical)business.industryHuman epidermal growth factorTrastuzumabmedicine.diseaseOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisCancer researchFemalebusiness030215 immunologymedicine.drugConjugateJournal of Oncology Pharmacy Practice
researchProduct

AB1197 Changes in Lumbar Spinopelvic Pattern of Movement Influence the Flexion Relaxation of the Erector Spinae

2015

Background In healthy subjects, the erector spinae muscles (ES) exhibits a relaxation of its electrical activity when the trunk is nearby its full flexion. Objectives To find out the influence of exhibiting a lumbar spine or a pelvis dominant pattern of movement during trunk flexion from upright position on the appearance of the myoelectric relaxation of the erector spinae. In healthy subjects, the erector spinae muscles (ES) exhibits a relaxation of its electrical activity when the trunk is nearby its full flexion. Objectives To find out the influence of exhibiting a lumbar spine or a pelvis dominant pattern of movement during trunk flexion from upright position on the appearance of the my…

musculoskeletal diseasesRelaxation (psychology)business.industryImmunologyAnatomyFlexion relaxationmusculoskeletal systemTrunkGeneral Biochemistry Genetics and Molecular BiologySagittal planeLumbarmedicine.anatomical_structureRheumatologyErector spinae musclesImmunology and AllergyMedicineLumbar spinebusinessPelvisAnnals of the Rheumatic Diseases
researchProduct

Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model

2012

SummaryMyotonic dystrophy type 1 (DM1) is a genetic disease caused by the pathological expansion of a CTG trinucleotide repeat in the 3' UTR of the DMPK gene. In the DMPK transcripts, the CUG expansions sequester RNA-binding proteins into nuclear foci, including transcription factors and alternative splicing regulators such as MBNL1. MBNL1 sequestration has been associated with key features of DM1. However, the basis behind a number of molecular and histological alterations in DM1 remain unclear. To help identify new pathogenic components of the disease, we carried out a genetic screen using a Drosophila model of DM1 that expresses 480 interrupted CTG repeats, i(CTG)480, and a collection of…

musculoskeletal diseasesSarcomerescongenital hereditary and neonatal diseases and abnormalitiesNeuroscience (miscellaneous)lcsh:MedicineMedicine (miscellaneous)RNA-binding proteinGenes InsectBiologyMyotonic dystrophyGeneral Biochemistry Genetics and Molecular BiologyAnimals Genetically Modifiedchemistry.chemical_compoundImmunology and Microbiology (miscellaneous)RNA interferencelcsh:PathologymedicineMBNL1AnimalsDrosophila ProteinsHumansMyotonic DystrophyGeneticsMuscleslcsh:RAlternative splicingNuclear ProteinsRNA-Binding ProteinsEpistasis Geneticmedicine.diseaseDisease Models AnimalchemistryGene Knockdown TechniquesDrosophilaFemaleRNA InterferenceTrinucleotide repeat expansionTrinucleotide Repeat ExpansionDrosophila Proteinlcsh:RB1-214Genetic screenResearch ArticleDisease Models & Mechanisms
researchProduct